For US Healthcare Professionals Only

The safety profile of YUPELRI® (revefenacin) inhalation solution has been demonstrated in
3 clinical studies

  • Safety database included 2,285 patients with COPD in two 12-week efficacy studies and one 52-week long-term safety study1*
  • A total of 730 patients received YUPELRI 175 mcg once daily1

Adverse events from two 12-week placebo-controlled efficacy trials (N=813)1

Yupelri.adverse.incidence.png

Fewer patients discontinued treatment with YUPELRI (13%) than with placebo (19%)1

Safety results from a 52-week, long-term trial vs tiotropium (N=1,055)1

  • YUPELRI was studied in a 52-week open-label active control safety study in patients with COPD (YUPELRI 175 mcg QD, n=335; tiotropium 18 mcg QD, n=356)
  • The adverse reactions reported in the long-term safety trial were consistent with those observed in the 12-week placebo-controlled studies

*Included patients who received an investigational 88 mcg/day dose of revefenacin

Indication

See more See Less

YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

For additional information please contact us at 800-395-3376.

I%20thought%20this%20might%20interest%20you
For%20healthcare%20professionals,%20learn%20about%20YUPELRI%C2%AE%20(revefenacin)%20inhalation%20solution%20at%20www.yupelrihcp.com.%20Read%20Important%20Safety%20Information%20and%20full%20Prescribing%20Information.